消栓肠溶胶囊对缺血性中风气虚血瘀型患者血液流变学及凝血功能的影响

目的:观察消栓肠溶胶囊对缺血性中风气虚血瘀型患者血液流变学和凝血功能的影晌。方法:缺血性中风气虚血瘀型患者80例随机分为观察组和对照组,各40例。对照组给予常规治疗,观察组在对照组治疗的基础上加用消栓肠溶胶囊,0.4 g/次,3次/d。两组患者均连续治疗30 d。于治疗前后评估神经功能缺损评分(MESSS),Bartbel指数量表(MBI),检测血流变学指标全血黏度高切,中切,低切,血浆黏度,红细胞压积(HCT),纤维蛋白原(Fib),红细胞沉降率(ESR)],凝血指标凝血酶原时间(PT),活化部分凝血酶时间(APTT),血小板聚集率(PAR)及D-二聚体]及疗效指标(梗死灶体积,MESSS评分及MBI)。结果:治疗前两组患者的血流变学指标(全血黏度高切,中切,低切,血浆黏度,HCT,Fib及ESR),凝血指标(全血黏度高切,中切,低切,血浆黏度,HCT,Fib及ESR)及疗效指标(梗死灶体积,MESSS评分及MBI)比较差异无统计学意义,具有可比性;治疗30 d后,观察组的总有效率高于对照组(P0.05);观察组的血流变学、凝血及疗效指标均优于对照组(P0.01,P0.05);观察组未发现明显的不良反应。结论:消栓肠溶胶囊治疗缺血性中风安全有效,改善血流变学和抗凝血功能可能为其作用机制之一。

Effect of Xiaoshuan Changrong Capsule on Hemorheology and Coagulation Function in Patients With Qi-deficiency and Blood-stasis Type Cerebral Ischemic Stroke

Objective: To observe the effect of Xiaoshuan Changrong capsule on hemorheology and coagulation function in patients with Qi-deficiency and blood-stasis type cerebral ischemic stroke. Method: Totally eighty patients with Qi-deficiency and blood-stasis type cerebral ischemic stroke were randomly divided into the observation group and the control group, with 40 cases in each group. The control group was given the conventional therapy;while the observation group was given Xiaoshuan Changrong capsule, 0.4 g once, three times daily, in addition to the therapy of the control group. Both groups were treated for 30 days. Before and after the treatment, nerve function defect scale (MESSS), modified barther index(MBI) were assessed, and hemorheological indexes (whole blood viscosity high shear, low shear, plasma viscosity, hematocrit(HCT),fibrinogen(Fib),erythrocyte sedimentation rate(ESR), coagulation indexes prothrombin time(PT), activated partial thromboplastin time(APTT), platelet oggregation rate(PAR) and D-dimmer] and therapeutic indexes (infarct volume, MESSS score and MBI) were monitored. Result: Before the treatment, hemorheological indexes whole blood viscosity high shear, low shear, plasma viscosity, HCT, Fib and ESR), coagulation indexes PT,APTT,PAR and D-dimmer) and therapeutic indexes (infarct volume, MESSS score and MBI) showed no significant differences between both groups, with the comparability. After the 30-day treatment, total efficiency in the observation group was higher than that in the control group (P<0.05),and hemorheology indexes, coagulation indexes and therapeutic effect indexes in the observation group were superior to that in the control group (P<0.05, P<0.01), with no obvious adverse reaction in the observation group. Conclusion: Xiaoshuan Changrong capsule is safe and effective in treating cerebral ischemic stroke. Its action mechanism may be correlated with the improvement in blood rheology and anticoagulant function. Key words] Xiaoshuan Changrong capsules;cerebral ischemic stroke;Qi-deficiency and blood-stasis;hemorheology;blood coagulation